Creative Biolabs is pioneering a dual-model approach in in vitro modeling by integrating 3D organoid and precision-cut tissue slice (PCTS) models, aiming to bridge the gap between experimental data and clinical realities. This innovative strategy addresses the limitations of traditional models by offering more physiologically relevant and translatable data for precision medicine research.
3D organoid models, derived from stem cells or patient tumor tissues, provide mini organs with defined structures and functions, making them ideal for disease modeling and targeted drug testing. Creative Biolabs offers a variety of organoid models, including 3D Tumor Organoid Models for drug sensitivity assessment and Customized 3D Organoid Models developed from iPSCs or client-provided cells for bespoke research needs.
However, organoids are not a one-size-fits-all solution. PCTS models, which preserve the anatomical architecture and cellular activity of fresh tissues, are indispensable for investigating short-term effects and drug distribution within specific organs. Creative Biolabs' PCTS models cover key organs and can be customized from healthy or diseased tissues, providing a versatile platform for early drug screening.
This dual-model approach enables researchers to quickly assess drug efficacy and toxicity with PCTS models before delving into mechanisms and long-term effects with organoids, creating a scientific feedback loop. As the biopharma industry shifts towards human-relevant models, Creative Biolabs' 3D biology platform stands as a critical partner in advancing precision medicine from model building to result translation.
For more information on 3D biological modeling, visit https://www.creative-biolabs.com/3d-biology/.
